We are live on ! Find out more
TNDM icon

Tandem Diabetes Care

273 hedge funds and large institutions have $2.93B invested in Tandem Diabetes Care in 2019 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 94 increasing their positions, 87 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 33

5% more funds holding

Funds holding: 261273 (+12)

3.78% more ownership

Funds ownership: 80.97%84.75% (+3.8%)

8% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 87

7% more call options, than puts

Call options by funds: $59.2M | Put options by funds: $55.1M

3% less capital invested

Capital invested by funds: $3.03B → $2.93B (-$102M)

13% less funds holding in top 10

Funds holding in top 10: 87 (-1)

Holders
273
Holders Change
+12
Holders Change %
+4.6%
% of All Funds
5.99%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.15%
New
46
Increased
94
Reduced
87
Closed
33
Calls
$59.2M
Puts
$55.1M
Net Calls
+$4.03M
Net Calls Change
-$39.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$322M -$49M -767,532 -12%
BlackRock
2
BlackRock
New York
$251M +$12.8M +199,865 +5%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$122M +$12.4M +194,257 +10%
FAM
4
Fred Alger Management
New York
$116M -$13.7M -215,252 -10%
Federated Hermes
5
Federated Hermes
Pennsylvania
$89.3M -$1.69M -26,482 -2%
State Street
6
State Street
Massachusetts
$77.6M -$796K -12,464 -0.9%
Renaissance Technologies
7
Renaissance Technologies
New York
$76.3M +$25.3M +395,700 +44%
TCM
8
TimesSquare Capital Management
New York
$73.1M +$6.56M +102,758 +9%
RG
9
Redmile Group
California
$68.4M -$359K -5,631 -0.5%
CCM
10
Consonance Capital Management
New York
$60.3M +$65.3M +1,022,257 New
EAM
11
Eagle Asset Management
Florida
$59.1M -$158K -2,479 -0.2%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$53.1M +$4.04M +63,344 +8%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$50.1M +$10.1M +158,211 +23%
Lord, Abbett & Co
14
Lord, Abbett & Co
New Jersey
$47.9M -$49.1M -768,995 -49%
CCI
15
Columbus Circle Investors
$45.2M -$2.14M -33,471 -4%
Northern Trust
16
Northern Trust
Illinois
$42.9M +$3.49M +54,639 +8%
CTA
17
Carillon Tower Advisers
Florida
$41.8M
AAM
18
Ardevora Asset Management
United Kingdom
$41.3M +$5.5M +86,200 +14%
O
19
OrbiMed
New York
$39.2M +$5.97M +93,600 +16%
GGHC
20
Gilder Gagnon Howe & Co
New York
$37M -$541K -8,468 -1%
Goldman Sachs
21
Goldman Sachs
New York
$36.3M +$2.73M +42,722 +7%
Citadel Advisors
22
Citadel Advisors
Florida
$34.3M +$14.1M +220,486 +61%
VOYA Investment Management
23
VOYA Investment Management
Georgia
$33.9M +$1.82M +28,458 +5%
N
24
Nuveen
North Carolina
$33.8M +$17.2M +269,645 +89%
PC
25
Polar Capital
United Kingdom
$33M +$15.8M +247,239 +79%

TNDM Hedge Fund Activity: Q3 2019 in Review

273 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q3 2019, worth a combined $2.93B — down 3.4% from $3.03B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new TNDM positions and 33 closed out — a net gain of 13 holders — while 94 added to existing stakes and 87 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $65.3M. The largest seller was Lord, Abbett & Co, cutting an estimated $49.1M.

  • 273 institutional investors held Tandem Diabetes Care (TNDM) as of Q3 2019, up from 261 in Q2 2019.
  • Funds reported $2.93B of Tandem Diabetes Care stock for Q3 2019, down 3.4% quarter-over-quarter.
  • 46 funds opened new Tandem Diabetes Care positions in Q3 2019 and 33 closed out, a net change of +13 holders.
  • The largest Tandem Diabetes Care buyer in Q3 2019 was Consonance Capital Management, an estimated $65.3M added.
  • The largest Tandem Diabetes Care seller in Q3 2019 was Lord, Abbett & Co, an estimated $49.1M sold.

Based on aggregated 13F filings for Q3 2019.